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Abstract
Background: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous
system (CNS). It is associated with local activation of microglia and astroglia, infiltration of activated
macrophages and T cells, active degradation of myelin and damage to axons and neurons. The
proposed role for CX3CL1 (fractalkine) in the control of microglia activation and leukocyte
infiltration places this chemokine and its receptor CX3CR1 in a potentially strategic position to
control key aspects in the pathological events that are associated with development of brain lesions
in MS. In this study, we examine this hypothesis by analyzing the distribution, kinetics, regulation
and cellular origin of CX3CL1 and CX3CR1 mRNA expression in the CNS of rats with an
experimentally induced MS-like disease, myelin oligodendrocyte glycoprotein (MOG)-induced
autoimmune encephalomyelitis (EAE).
Methods:  The expression of CX3CL1 and its receptor CX3CR1 was studied with in situ
hybridization histochemical detection of their mRNA with radio labeled cRNA probes in
combination with immunohistochemical staining of phenotypic cell markers. Both healthy rat brains
and brains from rats with MOG EAE were analyzed. In defined lesional stages of MOG EAE, the
number of CX3CR1 mRNA-expressing cells and the intensity of the in situ hybridization signal were
determined by image analysis. Data were statistically evaluated by ANOVA, followed by
Tukey\primes multiple comparison test.
Results: Expression of CX3CL1 mRNA was present within neuronal-like cells located throughout
the neuraxis of the healthy rat. Expression of CX3CL1 remained unaltered in the CNS of rats with
MOG-induced EAE, with the exception of an induced expression in astrocytes within inflammatory
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lesions. Notably, the brain vasculature of healthy and encephalitic animals did not exhibit signs of
CX3CL1 mRNA expression. The receptor, CX3CR1, was expressed by microglial cells in all regions
of the healthy brain. Induction of MOG-induced EAE was associated with a distinct accumulation
of CX3CR1 mRNA expressing cells within the inflammatory brain lesions, the great majority of
which stained positive for markers of the microglia-macrophage lineage. Analysis in time-staged
brain lesions revealed elevated levels of CX3CR1 mRNA in microglia in the periplaque zone, as well
as a dramatically enhanced accumulation of CX3CR1 expressing cells within the early-active, late-
active and inactive, demyelinated lesions.
Conclusion: Our data demonstrate constitutive and regulated expression of the chemokine
CX3CL1 and its receptor CX3CR1 by neurons/astrocytes and microglia, respectively, within the
normal and inflamed rat brain. Our findings propose a mechanism by which neurons and reactive
astrocytes may control migration and function of the surrounding microglia. In addition, the
accumulation of CX3CR1 expressing cells other than microglia within the inflammatory brain
lesions indicate a possible role for CX3CL1 in controlling invasion of peripheral leucocytes to the
brain.
Background
Chemokines are key mediators controlling infiltration of
leukocytes to inflamed areas. They consist of a class of
related proteins that exert chemotactic properties on leu-
kocytes via interactions with select members of the G-pro-
tein coupled, cell membrane-spanning receptors
(GPCRs). The so far 50 identified chemokines are divided
into 4 subgroups, the XC, CC, CXC and CX3C chemok-
ines, and the corresponding GPCRs are accordingly
denominated XCR (presently one member), CCR (11
deorphanized members), CXCR (6 members) and CX3CR
(one single member). Synthesis of chemokines is rapidly
induced in damaged or infected tissues and the cell-spe-
cific expression of chemokine receptors combined with
the situation-specific production of their chemokine lig-
ands provide cues to attract appropriate cell populations
to combat invading organisms and neoplastic cells and to
clear and repair damaged tissues. Chemokines are also
thought to drive chronic inflammatory processes and this
have fuelled hopes that pharmacological intervention of
ligand-triggered activation of chemokine receptors may
serve to reduce clinical manifestations in disorders with
inflammatory components [1].
CX3CL1 (alternative names: fractalkine or neurotactin)
was identified in 1997 as a chemokine of 373 amino acids
with, for the chemokine family, an atypical structure, a
chemokine domain tethered on top of a mucin-like
domain which is followed by a single transmembrane
spanning domain and a short cytoplasmic tail [2-4].
CX3CL1 is expressed within the brain, heart, lung, kidney,
muscle and testis [4-8] where it interacts with a single
GPCR, CX3CR1 [9,10] to trigger chemotaxis and adhesion
[10-13] of CX3CR1 expressing cells, including neu-
trophils, monocytes, NK cells and Th-1 polarized T cells
[10,14]. Studies of expression profiles, functional role in
in vitro and in vivo systems and genetic associations to dis-
eases have provided promising clues to a potential role of
CX3CL1 and its receptor in, among others, rheumatoid
arthritis [15-17], allograft rejections [18] and atheroscle-
rosis [19-21].
The physiological role of CX3CL1 and its receptor in the
brain, however, is less clear. Expression of CX3CL1 within
the brain is localized to neurons [22-25], whereas CX3CR1
is expressed by brain microglia [6,24-26]. Axotomy of the
facial nerve trigger increased expression of CX3CL1 among
the severed motor neurons in the facial nucleus [6] and a
similar response was recently observed following intrapa-
renchymal injection of prion proteins [22]. Induction of
experimental autoimmune encephalomyelitis (EAE; an
animal model for multiple sclerosis) in the mouse has
also been associated with CX3CL1-like immunoreactivity
in blood vessels within the inflammatory brain lesions
[3]. This finding is complemented by the increased levels
of CX3CR1 mRNA in the spinal cord of rats with EAE, as
demonstrated by RNAse protection assay [27]. CX3CL1
has moreover been shown to regulate microglia functions,
including CX3CL1-induced mobilization of intracellular
Ca2+, chemotaxis and the inhibition of Fas-mediated
apoptosis in vitro [6,23,28]. This is reflected in the activa-
tion of microglia following injection of CX3CL1 in vivo to
the rat brain parenchyma [22], indicating a potential role
for CX3CL1 and CX3CR1 in mediating neuronal-micro-
glial cross talk under normal and pathological conditions.
In addition, previous claims of CX3CL1 expression in
endothelial cells [3,15,16,29-32], combined with CX3CR1
on monocytes and Th-1 cells [5,14-16,33,34] may indi-
cate a role in attracting pathogenic cells to sites of neu-
roinflammation, as well.
Multiple sclerosis (MS) is a chronic inflammatory disease
of the CNS. It is associated with local activation of micro-
glia and astroglia, infiltration of activated macrophagesJournal of Neuroinflammation 2005, 2:17 http://www.jneuroinflammation.com/content/2/1/17
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and T cells, active degradation of myelin and damage to
axons and neurons. The disease often develops from iso-
lated self-limiting episodes with various neurological
manifestations, including paralysis, to persistent, accentu-
ated loss of neurological functions. The neuroinflamma-
tory component of the disease is, at least in initial phases,
thought to mediate important aspects of the clinical man-
ifestations. The proposed role for CX3CL1 in the control
of microglia activation and leukocyte infiltration places
this chemokine/receptor pair in a potentially strategic
position to control key aspects in the pathological events
that are associated with development of brain lesions in
MS. In this study, we examine this hypothesis further by
analyzing the distribution, kinetics, regulation and cellu-
lar origin of CX3CL1 and CX3CR1 mRNA expression in the
CNS of rats with MOG-induced EAE. The expression of
CX3CL1 and its receptor was studied with in situ hybridi-
zation histochemical detection of their mRNA with radio
labeled cRNA probes in combination with immunohisto-
chemical staining of phenotypic cell markers. Our find-
ings suggest that CX3CL1 and its receptor may control
aspects of the neuroinflammatory processes in MOG-
induced EAE, and possibly also MS.
Methods
Animals
Inbred female DA.RT1av1 rats were obtained from B&K
Sollentuna, Stockholm, Sweden. All rats were housed
under specific pathogen-free conditions to keep the influ-
ence of additional environmental factors, beside immuni-
zation, as low as possible. Female DA rats 10–14 weeks of
age (150–200 g) were used. All animal experiments were
approved and performed in accordance with Swedish
national guidelines.
Preparation of MOG
The N-terminal sequence of rat MOG (amino acids 1–
125) was expressed in Escherichia coli and purified to
homogeneity by chelate chromatography [35]. The puri-
fied proteins in 6 M urea were then dialyzed against PBS
to obtain a preparation that was stored at -20°C.
Induction and assessment of EAE
Rats were anaesthetized with methoxyflurane and injected
intradermally at the base of the tail with 0.2 ml inoculum,
containing 20 µg recombinant rat MOG in saline, emulsi-
fied (1:1) with incomplete Freund's adjuvant (IFA; Difco,
Detroit, MI). Rats were clinically scored and weighted
daily from day 7 post- immunization (p.i.) until day 30
p.i. by two alternating investigators. The clinical scoring
was as follows: 0 = no illness, 1 = tail weakness or tail
paralysis, 2 = hind leg paraparesis, 3 = hind leg paralysis,
4 = complete paralysis, moribund state, or death. A dis-
ease remission was defined as an improvement in disease
score from either 3 or 4 to 1, or from 2, 3 or 4 to 0 that was
maintained for at least 2 days consecutively. A relapse was
defined as an increase in the clinical deficit of at least two
points that lasted for at least 2 days.
Histopathology
Tissues where obtained from healthy, non-immunized
rats or rats sampled on day 8, 13, 18, 21, 24, 29 and 40 p.i.
Rats were deeply anaesthetized with methoxyflurane and
subjected to perfusion via aorta with 4% paraformalde-
hyde. Organs were dissected out, routinely embedded in
paraffin wax and sectioned at 5 µm. Histopathological
evaluation was performed on transverse sections of the
forebrain, midbrain, brainstem and 17 different rostro-
caudal levels of the spinal cord, using hematoxylin and
eosin (HE), Luxol fast blue/-periodic acid Schiff's (PAS)
staining and Bielschowsky silver impregnation, to assess
inflammation, demyelination, and axonal pathology,
respectively [36,37].
Preparation of radioactively labeled cRNA probes
Preparation of radioactively labeled cRNA probes encod-
ing rat CX3CL1 and CX3CR1 was carried out as previously
described [38]. Briefly, antisense and sense cRNA probes
were transcribed in vitro with T3 or T7 RNA polymerase in
the presence of 35S-uridine triphosphate (35S-UTP; NEN –
DuMedical, Sollentuna, Sweden). After removal of unin-
corporated nucleotides by Quick Spin columns (Boe-
hringer -Mannheim, Indianapolis, IN), the specific
activities of all the probes were 1–3 × 109 dpm/ug. The
CX3CL1 and CX3CR1 cRNA probes were transcribed from
cDNA fragments cloned into pDP18 CU minus plasmid
vector (Ambion, Austin, Texas). These cDNA fragments
correspond to a 450 base pair cDNA fragment of rat
CX3CL1 (from 20–469 bp, GeneBank accession number
AF030358) and a 882 base pair cDNA fragment of rat
CX3CR1 (GenBank accession number RN04808), respec-
tively, and were generated by RT-PCR using sequence-spe-
cific oligonucleotide primers. The identities of the cloned
cDNA fragments were finally confirmed by sequencing
and database comparisons. Restriction enzymes and RNA
polymerases were obtained from Promega (Madison, WI).
In situ hybridization and immunohistohistochemistry
To detect expression of CX3CL1 and CX3CR1 mRNA, in
situ  hybridization experiments were performed on sec-
tions from rat CNS. Hybridization and autoradiography
were carried out as previously described [39]. Briefly, tis-
sue sections were mounted on Superfrost plus slides
(Super Frost Plus, Pittsburgh, USA) and dried under vac-
uum overnight after deparaffination in xylene, pre-treated
in a microwave oven for 10 minutes at 97°C in 10 mM
SSC (pH 6.0) and dehydrated in ethanol. As controls,
radio labeled sense probes were transcribed in the sense
orientation and hybridized to slides as processed in paral-
lel. After application of 100 ul of hybridization solutionJournal of Neuroinflammation 2005, 2:17 http://www.jneuroinflammation.com/content/2/1/17
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containing 106 cpm of the cRNA probes, the slides were
cover slipped and incubated at 60°C for 16 to 20 hours.
Slides were subsequently washed in 4× standard saline cit-
rate (SSC, pH 7.0), digested in 20 υg/ml ribonuclease A
solution at 37°C for 30 minutes, washed in decreasing
concentrations of SSC, ending with 0.1 × SSC for 30 min-
utes at 70°C.
To identify the cellular phenotypes of the CX3CL1 or
CX3CR1 expressing cells, an immunohistochemical stain-
ing protocol was directly applied following the in situ
hybridization step, as previously described [39]. The fol-
lowing monoclonal primary antibodies were used: an
antibody specific for rat monocytes and macrophages
(ED-1, Serotec, diluted 1/500) or an antibody reactive
with glial fibrillary acidic protein (GFAP; G-A-5 diluted 1/
20; Boehringer – Mannheim). Analysis for expression of
CX3CL1 or CX3CR1 in neurons was performed, using an
antibody reactive to a neuronal specific protein (NeuN
[40]) diluted 1/100, Chemicon). Notably, as the NeuN
antigen proved to be sensitive to the present conditions
for combined labeling of mRNA and protein, we selected
to compare the distribution of NeuN protein and CX3CL1
or CX3CR1 mRNA independently on consecutive tissue
sections. A biotinylated sheep anti-mouse IgG antibody
(Life Sciences) served as the secondary reagent, with the
avidin biotin peroxidase (ABC) detection system (ABC
Elite, Vector Laboratories). Finally, a biotinylated lectin
(GSI-B4, Vector Laboratories) combined with the ABC
detection system was used for the detection of vascular
endothelial cells and macrophages and microglia in vari-
ous stages of activation. Parallel tissue sections were incu-
bated without primary antibody as control of specificity of
the staining.
Quantification of CX3CR1 mRNA-expressing cells in 
defined lesional stages
In a total of 5 brain sections from 4 rats in the relapse stage
(days 21–45), 10 inflammatory lesions were selected and
defined according to the stage of demyelinating activity as
previously described [41]. Briefly, early active (EA) lesions
were characterized by dense infiltrates of macrophages,
lymphocytes and microglia. Myelin sheaths were in the
process of disintegration and macrophages contained
luxol fast blue (LFB)-stained myelin degradation prod-
ucts. Late active (LA) lesions were still densely populated
by macrophages. Damaged myelin had been removed
from the axons and macrophages contained PAS-positive
myelin degradation products. Inactive completely demy-
elinated (DM) lesions showed no evidence of ongoing tis-
sue destruction. Inflammatory cells were present, but
macrophages did not display LFB or PAS staining. A single
plaque usually contained two or more different stages of
lesional activity (e.g. a central DM core surrounded by LA
and EA areas). The region in the immediate vicinity of the
plaques, showing no microscopic signs of demyelination,
was defined as periplaque white matter (PPWM). Repre-
sentative regions outside lesions and PPWM areas were
defined as normal white matter (NWM) and served as
internal controls. Following in situ hybridization and GSI-
B4 isolectin immunohistochemistry, the brain sections (3
from the cerebellum and pons, 1 from the frontal cortex,
1 from the thalamus) were captured with a Kappa DX-20
digital camera mounted on a Nikon E600 microscope. In
each of the defined lesions, the total number of GSI-B4+
cells as well as the numbers of GSI-B4+ and GSI-B4- cells
with positive hybridization signals for CX3CR1 were
counted in a standardized field of 1.9 × 104 µm2. The
intensity of the in situ hybridization signal was deter-
mined by counting areas of silver grains exceeding the
mean background level (as measured over 30 similarly
sized areas outside the cellular borders) + 11 SD (Access
Analysis system, Euromed Networks). In total, 8 EA
lesions, 8 LA lesions, 7 DM lesions, 8 PPWM areas and 9
NWM areas were included in the analysis. Data were sta-
tistically evaluated with ANOVA, followed by
Tukey\primes multiple comparison test. A P value < 0.05
was considered to be statistically significant.
Imaging
Bright-field images were captured with a Kappa DX-30
digital camera mounted on a Leica microscope. Digital
images were imported into Adobe Photoshop (v. 6.0),
where they were adjusted to balance and optimize bright-
ness, contrast, and sharpness. Individual files were
exported to Canvas (v. 8.0) for assembly into plates,
which were rendered at initial resolution of 300 dpi.
Results
Expression of mRNA encoding CX3CL1 and its receptor in 
the normal rat brain and spinal cord
Radio labeled antisense cRNA probes transcribed from
cDNA encoding rat CX3CL1 (Fig. 1) and its receptor,
CX3CR1 (data not shown), were initially hybridized in situ
to 5 µm tissue section obtained throughout the entire rat
brain and spinal cord. In the forebrain, cells expressing
high levels of CX3CL1 mRNA were detected throughout
the olfactory bulb, cerebral cortex, amygdala, globus-pal-
lidus and thalamus (Fig. 1). These cells manifested, with
few exceptions, a neuronal phenotype and co-distributed
with cells staining positive for the pan-neuronal marker
NeuN (exemplified in Fig. 5a, b at the spinal cord level).
High levels of CX3CL1 mRNA expression were also
detected in all pyramidal cells within the hippocampal
formation (Fig. 1). Significantly lower, but still clearly
detectable, levels of CX3CL1 mRNA were observed within
all aspects of the hypothalamus (Fig 1), with neurons
within the ventromedial nucleus displaying the strongest
labeling. In the mesencephalon, pons, medulla oblongata
and the spinal cord low to medium expression levels wereJournal of Neuroinflammation 2005, 2:17 http://www.jneuroinflammation.com/content/2/1/17
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uniformly detected in neuronal-like cells. A notable
exception was the cerebellum, where very low levels of
expression were detected within granule and pyramidal
cells whereas neuronal like cells in the deep cerebellar
nuclei expressed CX3CL1 mRNA at medium levels (Fig. 1).
Tissue sections hybridized in parallel with a radio labeled
cRNA probe transcribed in the sense orientation did not
reveal any hybridization signal above background levels
(data not shown).
Distribution of CX3CL1 mRNA expressing cells in the normal rat brain Figure 1
Distribution of CX3CL1 mRNA expressing cells in the normal rat brain. Coronal sections sampled at regular inter-
vals throughout the rostro-caudal extent of the normal rat brain hybridized with a 35S-labeled antisense-CRNA probe encod-
ing rat CX3CL1. Cells expressing mRNA encoding the chemokine are visualized as accumulations of white silver grain in this 
microscopic darkfield illumination at low magnification. The letters in each subfigure refer to the approximate levels according 
to the Paxinos stereotaxic brain atlas [61]. The highest levels of CX3CL1 mRNA were detected exclusively within the grey 
matter of the cerebral cortex (A:a, B:a, C:a, D:a), hippocampus (C:b), septum (B:c), thalamus (C:d) and striatum (B:e). Medium 
to low level expression was detected in the hypothalamus (C:f), pons (E:g), mesencephalon (D:h), medulla oblongata (not 
shown) and spinal cord (F:i). The cerebellum (E:j) was devoid of CX3CL1 expression, except for a low level of expression in 
the deep cerebellar nuclei. Parallel sections hybridized with a sense-transcribed CX3CL1 cRNA probe of equal specific activity 
did not reveal signals above background levels.Journal of Neuroinflammation 2005, 2:17 http://www.jneuroinflammation.com/content/2/1/17
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In addition to the expression of CX3CL1 mRNA among
neuronal-like cells within the rat brain and spinal cord, we
also detected low-to medium expression of CX3CL1 in a
few, solitary cells dispersed throughout the white matter
areas. These cells manifested a flattened, elongated mor-
phology (data not shown) and were not positively stained
in dual labeling experiments for CX3CL1 mRNA with phe-
notypic markers for macrophages/microglias or astro-
cytes. No expression of CX3CL1 mRNA was detected in
cells associated with the cerebral vasculature and the
meninges, including the endothelial cells themselves.
In consecutive tissue sections, in situ hybridization with a
radio labeled antisense cRNA probe encoding rat CX3CR1
revealed a low-to-medium expression within cells uni-
formly distributed throughout the entire neuraxis (data
not shown). The morphology of these cells, as well as
their positive labeling with GSI-B4 (Griffornia simplifolica
isolectin B4; stains microglia, macrophages and endothe-
lial cells) identified them as being inactive microglia (data
not shown). No detectable expression was observed over
other cells, including neurons and perivascular and
meningeal macrophages. Hybridization with a sense
cRNA probe transcribed from the same cDNA did not
reveal a signal above background levels (data not shown).
Expression of mRNA encoding CX3CL1 and its receptor in 
the CNS of rats with MOG-EAE
To explore the role of CX3CL1 and its receptor in the con-
trol of inflammatory cascades in MS, we examined their
expression and regulation in the CNS of rats with MOG-
induced EAE. In inbred DA rats, this disease manifested a
mostly relapsing-remitting disease course with an initial
paralytic episode, commencing around day 9–13 fol-
lowed by a partial or complete remission and then a
relapse of paresis (Fig. 2). In some rats the initial (acute)
paresis progressed directly into a prolonged paralysis
without any intervening remission of symptoms. In a
minority of the rats the acute episode spontaneously
resolved without further clinical signs of disease. The
acute phase of paresis was characterized histopathologi-
cally by astroglial and microglial activation and perivascu-
lar and submeningeal infiltration of lymphocytes,
macrophages and granulocytes. The inflammatory lesions
were mostly confined to the spinal cord and, in some rats,
the optic nerve and the cerebellar white matter. In rats that
exhibited a clinical relapse the inflammation followed
generally the pattern observed during the acute phase with
submeningeal and perivascular lesions. However, the
inflammatory reaction was often more extensive with
numerous confluent lesions that covered substantial areas
of the spinal white matter (Fig. 4), sometimes extending
into the grey matter areas. Inflammatory lesions were at
this stage closely associated with a marked demyelination
as well as axonal degeneration and loss of axonal density.
There was a distinct transition in cellular composition
observed within the inflammatory lesions, from predom-
inantly lymphocytes and granulocytes in the acute phase
lesions to an overwhelming presence of macrophages and
microglia with only a few granulocytes throughout the
inflammatory lesions during the clinical relapse. These
phagocytic cells exhibited obvious signs of uptake and
degradation of myelin components. This pattern of pare-
sis and histopathological alterations was generally in
accordance with previous studies [37,42], to which inter-
ested readers are referred for further details on the disease
pathology.
For the following studies we selected rats that conformed
to the typical relapsing-remitting disease phenotype (Fig.
2). In situ hybridization experiments revealed an uncom-
promised neuronal expression of CX3CL1 mRNA
throughout the entire CNS at all time points examined,
except for a tendency to a reduced level of expression in
grey matter regions which were notably infiltrated with
inflammatory cells (data not shown). In addition,
increased expression of CX3CL1 mRNA was evident in a
small number of non-neuronal cells within the inflamma-
tory lesions. Double-labeling experiments showed those
cells to stain positive for the astroglial marker glial fibril-
lary acidic protein, GFAP (Fig. 5). No hybridization signal
above background levels was detected in cells staining
Sampling of rats from various clinical stages of MOG-EAE Figure 2
Sampling of rats from various clinical stages of MOG-
EAE. Female DA rats (n = 20) were immunized with mineral 
oil-emulsified MOG and evaluated daily for severity of paraly-
sis. The arrows indicate selected time point at which subse-
quent kinetic analyses were performed. Rats (n = ≥ 3/group) 
which conformed in the clinical score curve above were per-
fused transcardially, tissues were dissected out and subjected 
to histopathological analysis of encephalitis and distribution 
of CX3CL1 and CX3CR1 expressing cells.Journal of Neuroinflammation 2005, 2:17 http://www.jneuroinflammation.com/content/2/1/17
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positive for GSI-B4 (e.g. macrophages/microglia and
endothelial cells). Tissue sections hybridized in parallel
with a sense-transcribed CX3CL1 cRNA probes did not
generate hybridization signals above background levels
(data not shown).
In situ hybridization with an antisense cRNA probe for
CX3CR1 demonstrated a low, constitutive expression of
the receptor in cells evenly distributed throughout the spi-
nal cord of healthy, non-immunized control rats (n = 3)
and presymptomatic rats (day 8 p.i, n = 3) (Fig. 3). The
morphology and positive staining for GSI-B4 identified
these cells as being inactive microglial cells. Rats exam-
ined at various stages following onset of clinically mani-
fest MOG-induced EAE (day 13 p.i, acute phase, n = 3; day
18 p.i, remission phase, n = 3; day 21 p.i, early relapse
phase, n = 3; day 24 p.i, mid relapse phase, n = 3; day 29
p.i, late relapse phase, n = 3) demonstrated a clear visual
increase in CX3CR1 mRNA levels per cell, as well as a nota-
bly increased density of CX3CR1 mRNA expressing cells,
within the inflammatory areas (Fig. 3 and 4). These aggre-
gates of CX3CR1 mRNA expressing cells were closely over-
lapping with the inflammatory lesions, being prominent
in the perivascular and submeningeal lesions during the
acute phase and with a few remaining lesions detectable
during the remission phase. In rats examined at various
time points of the relapse phase the aggregation of cells
expressing high levels of CX3CR1 mRNA closely followed
the areas of expanding lesions. The great majority of the
CX3CR1 mRNA expressing cells were at all stages of dis-
ease positively stained with GSI-B4 isolectin as well as
with the marker for active phagocytosis, ED-1. While all
GSI-B4 positive, CX3CR1 mRNA expressing cells in PPWM
regions displayed abundant ramified processes identify-
ing them as resident microglia, the morphology of the
GSI-B4 positive, CX3CR1 mRNA expressing cells within
EA, LA and DM lesions was consistent with both macro-
phages and microglia in an activated, phagocytic state
(Fig. 5). Occasional GSI-B4 negative, CX3CR1 mRNA
expressing cells were identified within the inflammatory
lesions. These cells had rounded or slightly elongated
nuclei and were of lymphocyte-like size. However, the
great majority of lymphocytes within the lesions did not
express CX3CR1mRNA (data not shown).
Distribution of CX3CR1 mRNA expressing cells in spinal cord of EAE rats Figure 3
Distribution of CX3CR1 mRNA expressing cells in spinal cord of EAE rats. In situ hybridization with a radiolabeled 
antisense cRNA probe encoding rat CX3CR1 to coronal sections from the lumbar segment of spinal cord of rats with MOG-
EAE. Cells expressing CX3CR1 mRNA are visualized by darkfield illumination of the photoemulsion-dipped slides.Journal of Neuroinflammation 2005, 2:17 http://www.jneuroinflammation.com/content/2/1/17
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Quantification of CX3CR1 mRNA-expressing cells in 
relation to the stage of demyelinating activity
To further characterize the distribution of CX3CR1 mRNA
expressing cells in MOG-induced EAE, we performed a
quantitative analysis in defined time-staged lesions. The
strongest expression of CX3CR1 mRNA was found in LA
areas, which contained a significantly higher density of
silver grains per square unit compared to EA areas (p <
0.05), DM areas (p < 0.05), PPWM regions (p < 0.001) and
NWM (p < 0.001) (Table 1, Figure 6a). In EA and DM
areas, the expression of CX3CR1 mRNA was significantly
higher compared to PPWM (p < 0.001) and NWM (p <
0.001). Although PPWM regions tended to show a higher
density of silver grains per square unit compared to NWM,
this difference was not statistically significant (Table 1,
Figure 6a). The actual number of CX3CR1 mRNA
expressing cells was three-fold higher in lesional areas
compared to PPWM and NWM but did not differ signifi-
cantly between EA, LA and DM. The overwhelming major-
ity of the CX3CR1 mRNA expressing cells stained positive
for GSI-B4 isolectin, identifying them as macrophages/
microglia (Table 1, Figure 6b). Although not all GSI-B4+
Sublesional distribution of CX3CR1 expressing cells Figure 4
Sublesional distribution of CX3CR1 expressing cells. Cellular infiltrations in the MOG-EAE rat brain (early relapse 
phase; day 21 post immunization) are observed with hematoxylin-eosin staining (upper left). Areas of active demyelination are 
revealed with Luxol fast blue/PAS staining (upper right). Actively phagocytozing cells are detected with immunohistochemical 
staining for ED-1 (lower left). This figure exemplifies the uneven distribution of CX3CR1 mRNA expressing cells (lower right) 
within the inflammatory aggregates.Journal of Neuroinflammation 2005, 2:17 http://www.jneuroinflammation.com/content/2/1/17
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Phenotyping of CX3CL1 and CX3CR1 expressing cells Figure 5
Phenotyping of CX3CL1 and CX3CR1 expressing cells. CX3CL1 mRNA expressing cells (upper left). Immunohisto-
chemical staining for the neuronal marker NeuN (upper right) performed on a parallel tissue section. Dual staining for CX3CL1 
mRNA and the astrocyte marker GFAP (lower left). Combined staining for CX3CR1 mRNA and the microglial marker GSI-B4 
isolectin (lower right).Journal of Neuroinflammation 2005, 2:17 http://www.jneuroinflammation.com/content/2/1/17
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cells expressed CX3CR1 mRNA, there was a significant (p
< 0.0001) correlation between the total number of GSI-
B4+ cells and the density of silver grains per square unit
(Table 1, Figure 6c).
Discussion
This study was designed to provide further insights into
the mechanisms of proinflammatory cell trafficking into
the CNS in MS. Our results show that the chemokine
CX3CL1 is expressed, and actively regulated, within
inflammatory CNS lesions in rats with MOG-induced
EAE, a rodent model of MS. In addition, we demonstrate
that cells expressing the CX3CR1 receptor, the majority of
which are potentially pathogenic phagocytic cells (i.e.
macrophages and/or microglia), are densely accumulat-
ing within the inflammatory lesions. This is consistent
with the hypothesis for a role of CX3CL1-CX3CR1 in the
local control of leukocyte infiltration into CNS lesions in
MOG-EAE rats, and possibly also MS. The constitutive
CX3CL1 and CX3CR1 expression by neurons and micro-
glia, respectively, even in the healthy rat brain, indicates a
potential mechanism whereby neurons control microglia
functions in the intact brain tissue, as well.
Our present findings of constitutive expression of CX3CL1
within the normal rat brain are in agreement with previ-
ous reports where CX3CL1 mRNA [24,25,43] and protein
[25,43] was demonstrated in most CNS neurons of
healthy rats. Similar results have also been obtained in the
mouse [4], rhesus monkey [25] and human [44] brain. It
is interesting to note that the levels of CX3CL1 mRNA dif-
fered greatly between different CNS regions, possibly indi-
cating a more pronounced role for neuronal CX3CL1 in
many forebrain structures, i.e. cerebral cortex, hippocam-
pus and striatum. Our demonstration that CX3CL1 mRNA
expression is induced in astrocytes within EAE lesions is
novel although the data are in accordance with study of
humans with HIV-associated dementia where CX3CL1
immunoreactivity was detected in astrocytes [45].
Induced expression of CX3CL1 in astrocytes was also
observed following intraparenchymal administration of
prion protein to the rat brain [22]. Co- cultivation of
human astrocytes and HIV-infected macrophages also
resulted in increased CX3CL1 immunoreactivity in astro-
cytes [45] and stimulation of rat [23] and human [46]
astrocytes with TNF-α and IL-1β or INF-γ in vitro has been
shown to up regulate CX3CL1 mRNA levels. A recent
immunohistochemical study of MS- and normal brain tis-
sue demonstrates a constituent CX3CL1 expression in
astrocytes and an increased expression in human adult
astrocyte cultures stimulated with pro-inflammatory
cytokines, but fail to demonstrate an upregulation of
CX3CL1 in MS patients [47]. However, these data collec-
tively indicate that astrocytes are capable of upregulating
CX3CL1 expression in inflamed or injured brain tissues.
Quantification of CX3CR1 mRNA expressing cells in defined  lesional stages Figure 6
Quantification of CX3CR1 mRNA expressing cells in 
defined lesional stages. (a) Density of silver grains 
(defined as areas exceeding the mean background + 11 SD) 
per square unit. (b) Number of CX3CR1 mRNA-expressing 
cells positively stained with GSI-B4 isolectin. (c) Correlation 
between total number of GSI-B4 cells and intensity of in situ 
hybridization signal (density of silver grains per square unit).
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In contrast to the observed expression of CX3CL1 in neu-
rons and astrocytes, we were not able to confirm previous
findings in EAE-afflicted mice [2] where endothelial
immunoreactivity for CX3CL1 was demonstrated within
inflamed brain lesions. Our findings are corroborated by
a recent study by Schwaeble et al. [25] in which no
CX3CL1 mRNA expression was detected within the
endothelium of EAE rats and mice. Possible explanations
for the contradictory results are differences in the sensitiv-
ity of the detection methods used or a potential non-spe-
cific, immunohistochemical cross-reactivity to other
proteins within the endothelium in the study by Bazan et
al. [2]. An alternative explanation would be if the secreted
form of CX3CL1, which is produced within the inflamed
brain parenchyma by neurons and astrocytes, is
transcytosed in an abluminal-to-luminal direction for
presentation to blood leukocytes in a similar manner to
what previously have been described for IL-8 and RANTES
[48]. It is, however, important to note that endothelial
cells outside the CNS have convincingly been demon-
strated to express CX3CL1 mRNA and protein [6,8,29-32].
CX3CL1 expression by the brain endothelium, which may
be below the detection limit of our assay, therefore
remains a tantalizing possibility by which blood leuko-
cytes may become attracted to migrate across the blood-
brain barrier into inflammatory CNS lesions of MOG EAE
rats.
Our present studies of CX3CR1 expression in the rat brain
confirm previous findings by Harrison et al [43], Nishiy-
ori et al [24] and others by demonstrating that microglia
express CX3CR1 mRNA constitutively within the normal
rat brain. These findings are also consistent with previous
demonstrations that CX3CL increases microglial migra-
tion [43], proliferation [49], survival [28], intracellular
recruitment of calcium [43] and secretion of cytokines
and metalloproteases [50]. In addition, we demonstrate
that CX3CR1 mRNA expressing cells are rapidly accumu-
lating at high densities within the inflammatory CNS
lesions of rats with MOG-induced EAE, confirming previ-
ous observations [41]. Interestingly, those cells amassed
throughout most kinetic stages of the lesions, with the
most conspicuous densities detected in the late active
stages. It is tempting to speculate about a down-regulatory
role of CX3CR1 expression in these late lesional stages,
based on the possible induction of nonsignaling CX3CR1
receptors [51]. The overwhelming majority of the CX3CR1
mRNA expressing cells within the lesional areas were
phagocytic cells (i.e. macrophages and/or microglias) as
demonstrated in double-labeling protocols with the GSI-
B4 isolectin or the ED-1 antibody. However, a few addi-
tional, non-GSI B4 labeled, CX3CR1 mRNA expressing
cells were also detected within the CNS lesions. These cells
may be speculated to correspond to infiltrating blood leu-
kocytes, such as NK cells, γδ T cells and/or terminally dif-
ferentiated CD4+ and CD8+ T cells, which previously have
been described to express CX3CL1 receptors and/or to
respond functionally upon CX3CL1 stimulation
[14,15,33,52,53]. However, the majority of the lym-
phocyte-like cells within the inflammatory lesions of the
present rats did not express CX3CR1 mRNA. Notably, no
expression of CX3CR1 mRNA was detected in GFAP-
labeled astrocytes (data not shown) or neuronal-like cells.
This contrasts to earlier findings of CX3CR1-like immuno-
reactivity within neurons of a rat model for prion disease
[22], in humans with HIV encephalitis [44] and in vitro
cultivated hippocampal neurons [54]. Hulshof et al. [47]
found weak to moderate neuronal CX3CR1-like immuno-
reactivity in the cortical grey matter, depending on the tis-
sue sample observed. Those data suggest that some
populations of neurons may indeed have the capacity to
express CX3CR1 under certain conditions.
Our present data are thus consistent with a role for
CX3CL1 in the rat CNS, both during healthy and inflam-
matory conditions. The constitutive expression of CX3CL1
and its receptor on neurons and microglia respectively
demonstrates that this chemokine-receptor pair is not
normally promoting inflammation. Their function may
under these conditions possibly be inert but CX3CL1,
which is normally linked physically to the neuronal
membrane via a spacer domain and a transmembrane
spanning motif [2], may alternatively mediate a direct
contact between neurons and neighboring microglia via
Table 1: Quantification of CX3CR1 mRNA expressing cells per square unit in rat EAE lesions (mean ± SEM)
NWM PPWM EA LA DM
Density of silver grains* per 1.9 × 104 µm2 39.4 ± 8.2 70.8 ± 7.2 220.3 ± 17.4a 276.3 ± 14.8b 208.4 ± 18.3a
Total number of GSI-B4+ cells per 1.9 × 104 µm2 11.0 ± 1.5 18.6 ± 1.6 65.3 ± 5.3a 68.1 ± 3.3a 59.8 ± 2.4a
Number of GSI-B4+/CX3CR1+ cells per 1.9 × 104 µm2 5 ± 0.9 12.4 ± 1.3 46.1 ± 7.4a 50.7 ± 3.3a 46.0 ± 3.8a
Number of GSI-B4-/CX3CR1+ cells per 1.9 × 104 µm2 0 ± 0 0 ± 0 0.8 ± 0.3 2.1 ± 0.7a 0.8 ± 0.4
*Silver grains: defined as areas exceeding the mean background level + 11 SD
a Statistically significant against NWM and PPWM
bStatistically significant against NWM, PPWM, EA and DMJournal of Neuroinflammation 2005, 2:17 http://www.jneuroinflammation.com/content/2/1/17
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its proadhesive properties [2]. Microglia are highly reac-
tive to insults to brain tissue and may inflict permanent
damage if not kept in check. A CX3CL1-mediated interac-
tion between neurons and surrounding microglias may
under healthy conditions provide a mechanism by which
neurons subdue the proinflammatory and neurotoxic
capacity of microglia. This notion is supported by recent
findings from in vitro studies where CX3CL1 inhibited
neuronal death following the stimulation in vitro of coc-
ultured microglia and hippocampal neurons with
lipopolysaccharide, LPS [55]. In this study, CX3CL1 was
also demonstrated to inhibit LPS stimulated activation of
microglia and associated TNF-α synthesis [55]. Moreover,
endogenous CX3CL1 has also been shown to inhibit the
increased levels of TNF-α and 8-isoprostane in the hip-
pocampus and cerebrospinal fluid following
intracerebroventricular injections of LPS [56]. In another
study, CX3CL1 protected neurons in vitro from the neuro-
toxic properties of platelet activating factor or the HIV
envelope protein, Tat [44]. In contrast, under conditions
where neurons and their axonal and dendritic projections
are injured, as is frequently the case in EAE and MS,
CX3CL1 is likely to be cleaved and released from the neu-
ronal membrane by locally acting metalloproteases [57].
This would create a chemotactic gradient that, in combi-
nation with other locally active proinflammatory media-
tors, may subserve the extensive accumulation and
activation of microglia within injured brain sites as
observed in the present study. In addition, the soluble
form of CX3CL1 may also contribute to the infiltration of
CX3CR1-expressing leukocytes, including macrophages
and effector T and NK cells. These cell types have crucial
roles in EAE as mediators of tissue destruction and/or dis-
ease regulation [58]. A functional significance of the solu-
ble CX3CL1 / CX3CR1-pathway is suggested by the present
demonstration of CX3CR1 expression in macrophage-like
cells and a small fraction of lymphocyte like cells. Interest-
ingly, concurrent studies have provided functional evi-
dences that CX3CR1 and its ligand serve as important
mediators of inflammation and pathology in animal
models models for atherosclerosis, transplant rejections,
glomerulonephritis and stroke [12,19,29,59]. Studies in
mice with targeted deletions of the CX3CL1 or CX3CR1
genes have, however, failed to provide information
regarding a contributory function for this chemokine-
receptor pair in EAE. CX3CL1 -/- mice [60] or CX3CR1 -/-
mice [18] developed EAE in a manner not significantly
deviating from wildtype mice. Furthermore, CX3CR1  -/-
mice did not manifest alterations in the microglia
responses around injured/dying motor neurons in a
peripheral axotomy model [53]. These studies suggest a
redundant compensatory mechanism by other chemotac-
tic factors or a more subtle role of this chemokine-recep-
tor pair in these mouse models for MS. The
aforementioned studies, which proposed a neuroprotec-
tive role for CX3CL1, would also warrant a more thorough
investigation of the long-term outcome as regards paraly-
sis and neuronal injuries in EAE-challenged CX3CL1, or
CX3CR1, deficient mice. A definite assignment of the role
of CX3CL1 and its receptor in normal and inflamed or
injured CNS conditions will await conceptual testing in
animal disease models using more informative tools such
as selective immunoneutralizing antisera, peptide antago-
nists or non-peptidergic CX3CR1 antagonists delivered at
various stages of the disease.
Conclusion
• We have provided data to demonstrate constitutive and
regulated expression of the chemokine CX3CL1 and its
receptor CX3CR1 by neurons/astrocytes and microglia,
respectively, within the normal and inflamed rat brain.
• Our findings propose a mechanism by which neurons
and reactive astrocytes may control migration and func-
tion of the surrounding microglia.
• In addition, the accumulation of CX3CR1 expressing
cells other than microglia within the inflammatory brain
lesions indicate a possible role for CX3CL1 in controlling
invasion of peripheral leucocytes to the brain.
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